WallStSmart

Boston Scientific Corp (BSX)vsQMMM Holdings Limited Ordinary Shares (QMMM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 1098552% more annual revenue ($20.61B vs $1.88M). BSX leads profitability with a 17.3% profit margin vs -150.1%. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

QMMM

Avoid

14

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued

Intrinsic value data unavailable for QMMM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

QMMM2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.3910/10

Safe zone — low bankruptcy risk

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

QMMM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
519.1x2/10

Trading at 519.1x book value

Return on EquityProfitability
-198.1%2/10

ROE of -198.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : QMMM

The strongest argument for QMMM centers on Debt/Equity, Altman Z-Score.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : QMMM

The primary concerns for QMMM are EPS Growth, Piotroski F-Score, Price/Book.

Key Dynamics to Monitor

BSX profiles as a mature stock while QMMM is a turnaround play — different risk/reward profiles.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (71/100 vs 14/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

QMMM Holdings Limited Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

QMMM Holdings Limited, provides digital media advertising and marketing production services primarily in Hong Kong.

Visit Website →

Want to dig deeper into these stocks?